XML 84 R73.htm IDEA: XBRL DOCUMENT v3.25.2
Segment Reporting - Sales from Products (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Segment Reporting Information [Line Items]        
Sales $ 15,806 $ 16,112 $ 31,335 $ 31,887
Increase in hedge revenue     16 118
Revenue related to the sale of the marketing rights     100 76
U.S.        
Segment Reporting Information [Line Items]        
Sales 8,836 7,876 17,359 15,354
Non-US        
Segment Reporting Information [Line Items]        
Sales 6,969 8,236 13,977 16,533
Operating Segments        
Segment Reporting Information [Line Items]        
Sales 15,696 15,890 30,922 31,408
Operating Segments | Pharmaceutical        
Segment Reporting Information [Line Items]        
Sales 14,050 14,408 27,688 28,415
Operating Segments | Animal Health        
Segment Reporting Information [Line Items]        
Sales 1,646 1,482 3,234 2,993
Operating Segments | U.S.        
Segment Reporting Information [Line Items]        
Sales 8,827 7,854 17,255 15,265
Operating Segments | U.S. | Pharmaceutical        
Segment Reporting Information [Line Items]        
Sales 8,328 7,399 16,254 14,336
Operating Segments | U.S. | Animal Health        
Segment Reporting Information [Line Items]        
Sales 499 455 1,001 929
Operating Segments | Non-US        
Segment Reporting Information [Line Items]        
Sales 6,869 8,036 13,667 16,143
Operating Segments | Non-US | Pharmaceutical        
Segment Reporting Information [Line Items]        
Sales 5,722 7,009 11,434 14,079
Operating Segments | Non-US | Animal Health        
Segment Reporting Information [Line Items]        
Sales 1,147 1,027 2,233 2,064
Operating Segments | Keytruda | Pharmaceutical        
Segment Reporting Information [Line Items]        
Sales 7,956 7,270 15,161 14,217
Operating Segments | Keytruda | U.S. | Pharmaceutical        
Segment Reporting Information [Line Items]        
Sales 4,749 4,412 9,057 8,531
Operating Segments | Keytruda | Non-US | Pharmaceutical        
Segment Reporting Information [Line Items]        
Sales 3,207 2,858 6,104 5,686
Operating Segments | Alliance revenue - Lynparza | Pharmaceutical        
Segment Reporting Information [Line Items]        
Sales 370 317 682 609
Operating Segments | Alliance revenue - Lynparza | U.S. | Pharmaceutical        
Segment Reporting Information [Line Items]        
Sales 174 153 319 288
Operating Segments | Alliance revenue - Lynparza | Non-US | Pharmaceutical        
Segment Reporting Information [Line Items]        
Sales 195 165 363 321
Operating Segments | Alliance revenue - Lenvima | Pharmaceutical        
Segment Reporting Information [Line Items]        
Sales 265 249 523 504
Operating Segments | Alliance revenue - Lenvima | U.S. | Pharmaceutical        
Segment Reporting Information [Line Items]        
Sales 183 177 368 349
Operating Segments | Alliance revenue - Lenvima | Non-US | Pharmaceutical        
Segment Reporting Information [Line Items]        
Sales 83 73 155 155
Operating Segments | Welireg | Pharmaceutical        
Segment Reporting Information [Line Items]        
Sales 162 126 300 211
Operating Segments | Welireg | U.S. | Pharmaceutical        
Segment Reporting Information [Line Items]        
Sales 138 116 261 194
Operating Segments | Welireg | Non-US | Pharmaceutical        
Segment Reporting Information [Line Items]        
Sales 24 10 39 17
Operating Segments | Alliance Revenue - Reblozyl | Pharmaceutical        
Segment Reporting Information [Line Items]        
Sales 107 90 226 161
Operating Segments | Alliance Revenue - Reblozyl | U.S. | Pharmaceutical        
Segment Reporting Information [Line Items]        
Sales 88 75 189 133
Operating Segments | Alliance Revenue - Reblozyl | Non-US | Pharmaceutical        
Segment Reporting Information [Line Items]        
Sales 19 15 37 28
Operating Segments | Gardasil/Gardasil 9 | Pharmaceutical        
Segment Reporting Information [Line Items]        
Sales 1,126 2,478 2,453 4,727
Operating Segments | Gardasil/Gardasil 9 | U.S. | Pharmaceutical        
Segment Reporting Information [Line Items]        
Sales 545 536 1,082 1,024
Operating Segments | Gardasil/Gardasil 9 | Non-US | Pharmaceutical        
Segment Reporting Information [Line Items]        
Sales 581 1,941 1,371 3,702
Operating Segments | ProQuad/M-M-R II/Varivax | Pharmaceutical        
Segment Reporting Information [Line Items]        
Sales 609 617 1,148 1,187
Operating Segments | ProQuad/M-M-R II/Varivax | U.S. | Pharmaceutical        
Segment Reporting Information [Line Items]        
Sales 481 490 903 928
Operating Segments | ProQuad/M-M-R II/Varivax | Non-US | Pharmaceutical        
Segment Reporting Information [Line Items]        
Sales 128 127 245 259
Operating Segments | Vaxneuvance | Pharmaceutical        
Segment Reporting Information [Line Items]        
Sales 229 189 459 408
Operating Segments | Vaxneuvance | U.S. | Pharmaceutical        
Segment Reporting Information [Line Items]        
Sales 136 99 275 260
Operating Segments | Vaxneuvance | Non-US | Pharmaceutical        
Segment Reporting Information [Line Items]        
Sales 93 90 184 148
Operating Segments | RotaTeq | Pharmaceutical        
Segment Reporting Information [Line Items]        
Sales 121 163 349 379
Operating Segments | RotaTeq | U.S. | Pharmaceutical        
Segment Reporting Information [Line Items]        
Sales 60 107 225 257
Operating Segments | RotaTeq | Non-US | Pharmaceutical        
Segment Reporting Information [Line Items]        
Sales 61 56 125 123
Operating Segments | Capvaxive | Pharmaceutical        
Segment Reporting Information [Line Items]        
Sales 129 0 236 0
Operating Segments | Capvaxive | U.S. | Pharmaceutical        
Segment Reporting Information [Line Items]        
Sales 129 0 235 0
Operating Segments | Capvaxive | Non-US | Pharmaceutical        
Segment Reporting Information [Line Items]        
Sales 0 0 1 0
Operating Segments | Pneumovax 23 | Pharmaceutical        
Segment Reporting Information [Line Items]        
Sales 38 59 79 120
Operating Segments | Pneumovax 23 | U.S. | Pharmaceutical        
Segment Reporting Information [Line Items]        
Sales 5 11 3 17
Operating Segments | Pneumovax 23 | Non-US | Pharmaceutical        
Segment Reporting Information [Line Items]        
Sales 33 48 76 103
Operating Segments | Bridion | Pharmaceutical        
Segment Reporting Information [Line Items]        
Sales 461 455 902 895
Operating Segments | Bridion | U.S. | Pharmaceutical        
Segment Reporting Information [Line Items]        
Sales 411 351 789 680
Operating Segments | Bridion | Non-US | Pharmaceutical        
Segment Reporting Information [Line Items]        
Sales 50 104 113 215
Operating Segments | Prevymis | Pharmaceutical        
Segment Reporting Information [Line Items]        
Sales 228 188 436 362
Operating Segments | Prevymis | U.S. | Pharmaceutical        
Segment Reporting Information [Line Items]        
Sales 115 90 217 165
Operating Segments | Prevymis | Non-US | Pharmaceutical        
Segment Reporting Information [Line Items]        
Sales 113 98 219 197
Operating Segments | Dificid | Pharmaceutical        
Segment Reporting Information [Line Items]        
Sales 96 92 179 165
Operating Segments | Dificid | U.S. | Pharmaceutical        
Segment Reporting Information [Line Items]        
Sales 83 79 155 147
Operating Segments | Dificid | Non-US | Pharmaceutical        
Segment Reporting Information [Line Items]        
Sales 13 12 24 17
Operating Segments | Zerbaxa | Pharmaceutical        
Segment Reporting Information [Line Items]        
Sales 74 62 145 118
Operating Segments | Zerbaxa | U.S. | Pharmaceutical        
Segment Reporting Information [Line Items]        
Sales 45 33 87 67
Operating Segments | Zerbaxa | Non-US | Pharmaceutical        
Segment Reporting Information [Line Items]        
Sales 29 28 57 51
Operating Segments | Winrevair | Pharmaceutical        
Segment Reporting Information [Line Items]        
Sales 336 70 615 70
Operating Segments | Winrevair | U.S. | Pharmaceutical        
Segment Reporting Information [Line Items]        
Sales 323 70 591 70
Operating Segments | Winrevair | Non-US | Pharmaceutical        
Segment Reporting Information [Line Items]        
Sales 12 0 24 0
Operating Segments | Alliance revenue - Adempas/Verquvo | Pharmaceutical        
Segment Reporting Information [Line Items]        
Sales 123 106 229 203
Operating Segments | Alliance revenue - Adempas/Verquvo | U.S. | Pharmaceutical        
Segment Reporting Information [Line Items]        
Sales 108 98 205 188
Operating Segments | Alliance revenue - Adempas/Verquvo | Non-US | Pharmaceutical        
Segment Reporting Information [Line Items]        
Sales 15 8 23 16
Operating Segments | Adempas | Pharmaceutical        
Segment Reporting Information [Line Items]        
Sales 80 72 147 142
Operating Segments | Adempas | U.S. | Pharmaceutical        
Segment Reporting Information [Line Items]        
Sales 0 0 0 0
Operating Segments | Adempas | Non-US | Pharmaceutical        
Segment Reporting Information [Line Items]        
Sales 80 72 147 142
Operating Segments | Lagevrio | Pharmaceutical        
Segment Reporting Information [Line Items]        
Sales 83 110 185 460
Operating Segments | Lagevrio | U.S. | Pharmaceutical        
Segment Reporting Information [Line Items]        
Sales 30 15 66 60
Operating Segments | Lagevrio | Non-US | Pharmaceutical        
Segment Reporting Information [Line Items]        
Sales 52 95 119 400
Operating Segments | Isentress/Isentress HD | Pharmaceutical        
Segment Reporting Information [Line Items]        
Sales 86 89 176 200
Operating Segments | Isentress/Isentress HD | U.S. | Pharmaceutical        
Segment Reporting Information [Line Items]        
Sales 48 43 99 93
Operating Segments | Isentress/Isentress HD | Non-US | Pharmaceutical        
Segment Reporting Information [Line Items]        
Sales 38 46 77 107
Operating Segments | Delstrigo | Pharmaceutical        
Segment Reporting Information [Line Items]        
Sales 83 60 150 116
Operating Segments | Delstrigo | U.S. | Pharmaceutical        
Segment Reporting Information [Line Items]        
Sales 14 14 29 26
Operating Segments | Delstrigo | Non-US | Pharmaceutical        
Segment Reporting Information [Line Items]        
Sales 70 45 121 89
Operating Segments | Pifeltro | Pharmaceutical        
Segment Reporting Information [Line Items]        
Sales 41 39 86 81
Operating Segments | Pifeltro | U.S. | Pharmaceutical        
Segment Reporting Information [Line Items]        
Sales 25 27 57 56
Operating Segments | Pifeltro | Non-US | Pharmaceutical        
Segment Reporting Information [Line Items]        
Sales 16 12 29 25
Operating Segments | Belsomra | Pharmaceutical        
Segment Reporting Information [Line Items]        
Sales 40 53 90 99
Operating Segments | Belsomra | U.S. | Pharmaceutical        
Segment Reporting Information [Line Items]        
Sales 18 19 31 33
Operating Segments | Belsomra | Non-US | Pharmaceutical        
Segment Reporting Information [Line Items]        
Sales 21 34 58 66
Operating Segments | Simponi | Pharmaceutical        
Segment Reporting Information [Line Items]        
Sales 0 172 0 356
Operating Segments | Simponi | U.S. | Pharmaceutical        
Segment Reporting Information [Line Items]        
Sales 0 0 0 0
Operating Segments | Simponi | Non-US | Pharmaceutical        
Segment Reporting Information [Line Items]        
Sales 0 172 0 356
Operating Segments | Remicade | Pharmaceutical        
Segment Reporting Information [Line Items]        
Sales 0 35 0 74
Operating Segments | Remicade | U.S. | Pharmaceutical        
Segment Reporting Information [Line Items]        
Sales 0 0 0 0
Operating Segments | Remicade | Non-US | Pharmaceutical        
Segment Reporting Information [Line Items]        
Sales 0 35 0 74
Operating Segments | Januvia | Pharmaceutical        
Segment Reporting Information [Line Items]        
Sales 372 405 921 824
Operating Segments | Januvia | U.S. | Pharmaceutical        
Segment Reporting Information [Line Items]        
Sales 216 177 561 361
Operating Segments | Januvia | Non-US | Pharmaceutical        
Segment Reporting Information [Line Items]        
Sales 155 227 360 463
Operating Segments | Janumet | Pharmaceutical        
Segment Reporting Information [Line Items]        
Sales 251 224 498 475
Operating Segments | Janumet | U.S. | Pharmaceutical        
Segment Reporting Information [Line Items]        
Sales 68 17 133 55
Operating Segments | Janumet | Non-US | Pharmaceutical        
Segment Reporting Information [Line Items]        
Sales 184 208 366 420
Operating Segments | Other pharmaceutical | Pharmaceutical        
Segment Reporting Information [Line Items]        
Sales 584 618 1,313 1,252
Operating Segments | Other pharmaceutical | U.S. | Pharmaceutical        
Segment Reporting Information [Line Items]        
Sales 136 190 317 354
Operating Segments | Other pharmaceutical | Non-US | Pharmaceutical        
Segment Reporting Information [Line Items]        
Sales 450 430 997 899
Operating Segments | Livestock | Animal Health        
Segment Reporting Information [Line Items]        
Sales 961 837 1,885 1,686
Operating Segments | Livestock | U.S. | Animal Health        
Segment Reporting Information [Line Items]        
Sales 190 168 384 334
Operating Segments | Livestock | Non-US | Animal Health        
Segment Reporting Information [Line Items]        
Sales 771 669 1,501 1,352
Operating Segments | Companion Animal | Animal Health        
Segment Reporting Information [Line Items]        
Sales 685 645 1,349 1,307
Operating Segments | Companion Animal | U.S. | Animal Health        
Segment Reporting Information [Line Items]        
Sales 309 287 617 595
Operating Segments | Companion Animal | Non-US | Animal Health        
Segment Reporting Information [Line Items]        
Sales 376 358 732 712
Corporate, Non-Segment        
Segment Reporting Information [Line Items]        
Sales 110 222 413 479
Corporate, Non-Segment | U.S.        
Segment Reporting Information [Line Items]        
Sales 9 22 104 89
Corporate, Non-Segment | Non-US        
Segment Reporting Information [Line Items]        
Sales $ 100 $ 200 $ 310 $ 390